WO2020237181A1 - Procédés de traitement d'allergie à l'arachide par immunothérapie orale avec entretien à faible dose - Google Patents

Procédés de traitement d'allergie à l'arachide par immunothérapie orale avec entretien à faible dose Download PDF

Info

Publication number
WO2020237181A1
WO2020237181A1 PCT/US2020/034311 US2020034311W WO2020237181A1 WO 2020237181 A1 WO2020237181 A1 WO 2020237181A1 US 2020034311 W US2020034311 W US 2020034311W WO 2020237181 A1 WO2020237181 A1 WO 2020237181A1
Authority
WO
WIPO (PCT)
Prior art keywords
dose
peanut protein
phase
peanut
subject
Prior art date
Application number
PCT/US2020/034311
Other languages
English (en)
Inventor
Daniel Adelman
Original Assignee
Aimmune Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimmune Therapeutics, Inc. filed Critical Aimmune Therapeutics, Inc.
Publication of WO2020237181A1 publication Critical patent/WO2020237181A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
    • A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Definitions

  • Described herein are methods for treating peanut allergy using an oral immunotherapy comprising a maintenance phase.
  • Peanut allergy is a hypersensitivity reaction of the immune system to peanut protein. Peanut allergy often develops in childhood and is usually a lifelong affliction. Allergic reactions to peanut can be severe and life threatening, and are a major source of severe food- induced anaphylaxis.
  • Oral immunotherapy is a promising new treatment for peanut allergy.
  • AR101 an oral immunotherapy for treating peanut allergy, has been shown to be both safe and effective in clinical trials. See, for example, Bird et al., Efficacy and Safety ofAR.101 in Oral Immunotherapy for Peanut Allergy: Results of
  • Peanut OIT includes exposing patients to peanut protein to gradually induce desensitization, reducing the risk of a serious reaction upon accidental exposure to peanut.
  • subjects undergoing peanut OIT can experience an adverse reaction during the course of therapy.
  • Subjects who experience adverse reactions may discontinue the oral immunotherapy by necessity (e.g., due to severe anaphylaxis) or due to choice (e.g., due to other untoward clinical occurrences).
  • Oral immunotherapy methods that lower incidence of adverse events can greatly expand the population of patients that can be treated for peanut allergy.
  • Described herein is a method of treating a subject for a peanut allergy by an oral immunotherapy comprising an up-dosing phase and a maintenance phase, the method comprising daily administration to the subject of a maintenance phase dose of about 10 mg to about 100 mg peanut protein during the maintenance phase of the oral immunotherapy.
  • the maintenance phase dose of peanut protein is about 10 mg. In some embodiments, the maintenance phase dose of peanut protein is about 30 mg. In some embodiments, the maintenance phase dose of peanut protein is about 60 mg. In some embodiments, the maintenance phase dose of peanut protein is about 100 mg.
  • the subject is less than 18 years old. In some embodiments, the subject is between about 6 months old and less than 18 years old. In some embodiments, the subject is between about 4 and about 17 years old.
  • the maintenance phase is at least 3 months. In some embodiments, the maintenance phase is at least 6 months. In some embodiments, the maintenance phase is at least 1 year.
  • the up-dosing phase comprises at least one dose of about 3 mg to about 100 mg. In some embodiments, the up-dosing phase comprises at least one dose of about 100 mg to about 300 mg.
  • the up-dosing phase is between 1 day and 6 months. In some embodiments, the up-dosing phase is between 6 months and 2 years.
  • the oral immunotherapy further comprises an initial escalation phase.
  • Described herein are methods of treating a subject for a peanut allergy by an oral immunotherapy comprising an up-dosing phase and a maintenance phase.
  • the peanut protein dose administered during the maintenance phase can be, for example, between about 10 mg to about 100 mg peanut protein.
  • Oral immunotherapy is a method of inducing desensitization to an allergen in a subject by regular exposure of the subject to increasing doses of the allergen.
  • protocols for OIT typically involve an up-dosing phase (also called a build-up phase) and a maintenance phase.
  • the OIT further includes an initial escalation phase, although this phase is optional and not required for treatment.
  • the initial escalation phase involves exposure to small doses of peanut protein under clinical supervision to determine the sensitivity of the patient to the peanut protein. This initial escalation phase generally occurs over the course of several (e.g., three or more) hours to two days.
  • peanut OIT includes a maintenance phase involving the long-term administration of peanut protein.
  • the primary goal of oral immunotherapy is establishing a desensitized state, wherein the subject being treated is less likely to suffer a severe or life-threatening allergic reaction upon accidental exposure to peanut protein.
  • a low-dose maintenance phase less than 300 mg peanut protein per dose, such as between 10 mg and 100 mg peanut protein per dose, may be better tolerated, without reducing the effectiveness of the OIT.
  • Reference to“about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, description referring to “about X” includes description of“X”.
  • the term“desensitized” is used herein to refer to an increased reaction threshold to a food allergen by a subject as a result of an oral immunotherapy for the food allergen.
  • Desensitization to a food allergen can be tested using methods known in the art, including an oral food challenge. Desensitization may be partial, wherein the subject tolerates an increased amount of the food allergen compared to prior to treatment, but still reacts to higher doses of the food allergen; or the desensitization may be complete, wherein the patient tolerates all tested doses of the food allergen.
  • “effective,”“efficacy,” or“effectiveness” are used herein to refer to the ability of a therapy to induce immune modulation, such as desensitization, or sustain a desired immune state, such as a desensitized state, unless otherwise indicated.
  • “maintenance phase” refers to a phase of a peanut protein oral immunotherapy that includes administration of peanut protein (i.e., a maintenance dose) to the patient, and occurs after completion of the up-dosing phase.
  • a“mild allergic adverse event” refers to an observed or experienced OGG-treatment-related allergic adverse event associated with transient discomfort, but does not require immediate medical intervention such as hospitalization or epinephrine, and does not substantially interfere with daily activities.
  • a“moderate allergic adverse event” refers to an observed or experienced OIT-treatment-related allergic adverse event that is associated with discomfort of a sufficient degree to interfere with daily activities and that may prompt medical intervention and/or additional observation.
  • the phrase“serious allergic adverse event” refers to an observed or experienced OIT-treatment-related allergic adverse event leading to anaphylaxis that requires hospitalization and/or administration of epinephrine or other life-saving medical intervention.
  • a subject is considered to tolerate the dose even if a mild allergic adverse event is observed or experienced.
  • the terms“treat,”“treating,” and“treatment” are used synonymously herein to refer to any action providing a benefit to a subject afflicted with a disease state or condition, including improvement in the condition through lessening, inhibition, suppression, or elimination of at least one symptom; delay in progression of the disease; delay in recurrence of the disease; inhibition of the disease; or partially or fully reducing a response or reaction to an allergen.
  • An“up-dosing phase” refers to a phase of an oral immunotherapy characterized by a series of increasing food allergen doses, beginning with administration of a dose of food allergen lower than the highest dose administered to the patient during the oral
  • a subject having a peanut allergy can be treated for the peanut allergy by
  • the dosing schedule for example the duration of the up dosing and/or maintenance phases, may vary between subjects depending on the age, health conditions, the nature and type of peanut allergy, concurrent interventions, complicating indications, etc.
  • the full length of the oral immunotherapy may vary between subjects depending on the age, health conditions, the nature and type of peanut allergy, concurrent interventions, and/or complicating indications, among others.
  • the therapy is generally multi-phasic, and includes at least an up-dosing phase and a maintenance phase.
  • the oral immunotherapies may further include an initial escalation phase preceding the up-dosing phase.
  • the size of the doses of the peanut protein composition administered in the up-dosing and maintenance phases can be adjusted as necessary based on the judgment of a subject’s medical caregiver and/or the needs of the subject.
  • Methods of diagnosing peanut allergy include immunological assays (such as peanut-specific IgE), skin prick tests, food challenges, and trial elimination diets.
  • immunological assays such as peanut-specific IgE
  • skin prick tests for diagnosis of peanut allergy by food challenge, the subject receives increasing doses of peanut protein.
  • An observed allergic reaction to the peanut protein during the food challenge indicates the subject has a peanut allergy and is a candidate for peanut oral immunotherapy.
  • the judgment of whether a subject reacts to a particular dose during the food challenge depends on the test criteria, which can vary.
  • a reaction in a food challenge can be judged by the severity of symptoms (e.g., mild, moderate, or severe) and/or the observability of the symptom (e.g., whether a symptom is subjectively reported by the patient or objectively observed by the medical caregiver).
  • severity of symptoms e.g., mild, moderate, or severe
  • observability of the symptom e.g., whether a symptom is subjectively reported by the patient or objectively observed by the medical caregiver.
  • a subject undergoing peanut OIT as described herein for treatment of a peanut allergy has a known or suspected peanut allergy.
  • the subject has previously attempted or completed a peanut protein OIT.
  • the previous peanut protein OIT was ineffective (for example, by failing to induce acceptable desensitization, producing unacceptable adverse reactions, or failing to impart adequate protection from accidental exposure to peanut protein), was terminated by the patient due to discomfort or necessity (for example, due to reaction to the peanut protein doses and/or due to adverse events during the course of OIT), or was terminated by the patient’s medical caregiver (for example, due to adverse reaction to peanut protein doses and/or due to adverse events during the course of OIT).
  • a subject undergoing peanut OIT as described herein for treatment of a peanut allergy may be treatment naive, having never undergone a peanut OIT for the treatment of a peanut allergy.
  • a subject being diagnosed for peanut allergy by diagnostic exposure to peanut protein, such as in a DBPCFC, but with no other history of clinical exposure to peanut protein, is still considered treatment naive after the diagnostic exposure for the purposes of this application.
  • the subject receiving the oral immunotherapy treatment for peanut allergy is a human subject.
  • the subject is about 12 months or older, such as about 12 months to about 48 months (for example, about 12 months to about 24 months, about 24 months to about 36 months, or about 36 months to about 48 months).
  • the subject is about 4 years or older.
  • the subject is between 4 years and less than 18 years old. In some embodiments, the subject is 18 years or older.
  • the up-dosing phase precedes the maintenance phase, and includes administration of a series of escalating doses to reach the maximum dose administered to the subject during the course of oral immunotherapy.
  • the length of time of the up-dosing phase can be adapted according to the needs of an individual patient, although it is generally completed in about 22 to about 40 weeks. For some patients, the up-dosing phase may last as long as 2 years or more.
  • the up-dosing phase may be extended, for example, if a patient experiences allergic adverse events after beginning a higher dose in the dosing series.
  • the up-dosing phase of a peanut OIT typically involves incrementally increasing the administered peanut protein dose after a period of time (e.g., approximately every 1-4 weeks).
  • a particular dose in the series is repeatedly (e.g., daily) administered to the patient until advancing to the next dose in the series.
  • the dose is decreased or the dose in the series is repeated for a period of time prior to advancing to the next dose in the series.
  • the rate of up-dosing (e.g., the length of time an individual dose in the series is administered or the size of the dose increment between doses in the series) may be adjusted based on one or more observed allergic adverse events.
  • the oral immunotherapy includes an initial escalation phase before the up dosing phase, wherein the subject is administered over the course of one or two days a series of escalating doses.
  • the initial escalation phase is distinguished from the up-dosing phase by a lower dose range, shorter intervals between dose escalations, and, typically, closer monitoring by the subject’s medical caregiver.
  • a two day initial escalation may comprise a series of doses from about 0.5 mg to about 6 mg peanut protein, such as individual doses of about 0.5 mg, about 1 mg, about 1.5 mg, about 3 mg, and about 6 mg peanut protein.
  • the highest tolerated dose of the initial escalation phase may be the first dose of the up dosing phase. If a subject does not tolerate at least a certain dose in the initial escalation phase, the subject may be excluded from the oral immunotherapy. For example, if a subject suffers a serious allergic adverse event after administration of the 0.5 mg, 1 mg, or 1.5 mg peanut protein dose, the subject may not be allowed to proceed to the up-dosing phase.
  • the purposes of the initial escalation phase include calibrating the doses of the up-dosing phase (e.g., the initial dose of the up-dosing phase), and ensuring the suitability of the subject for safely proceeding through an up-dosing phase.
  • the oral immunotherapies described herein include a maintenance phase in which a plurality of doses each comprising less than 300 mg peanut protein, such as between about 10 mg and about 100 mg of a peanut protein, are periodically administered to the subject after completion of an up-dosing phase.
  • the maintenance dose can be administered to the subject according to a regular schedule, for example once a day (i.e., daily).
  • Described herein is a method of treating a subject for a peanut allergy by an oral immunotherapy comprising an up-dosing phase and a maintenance phase, comprising periodic, preferably daily, administration to the subject of a low-dose maintenance phase dose of about 10 mg to about 100 mg peanut protein during at least part or all of a maintenance phase of a peanut oral immunotherapy.
  • the up-dosing phase of a peanut OIT is divided into sub-phases and typically involves incrementally increasing the peanut protein dose approximately every 1-4 weeks, although the rate of up-dosing (either faster or slower) may be adjusted based on observed adverse events.
  • the maintenance phase dose is the same as the dose of the final dose of the up-dosing phase. In some embodiments, the maintenance phase dose is less than the dose of the final dose of the up-dosing phase.
  • the final dose of the up-dosing phase is about 300 mg peanut protein, and the dose of the maintenance phase is between about 10 mg and about 100 mg peanut protein. In another example, the final dose of the up-dosing phase is about 100 mg peanut protein, and the dose of the maintenance phase is between about 10 mg and about 100 mg peanut protein.
  • the maintenance phase dose is administered for at least 12 weeks, at least 24 weeks, at least 36 weeks, at least 48 weeks, at least 60 weeks, or at least 72 weeks. In some embodiments, the maintenance phase dose is administered for 72 weeks or more. In some embodiments, the maintenance phase dose is administered for about 1 month to about 3 months, about 3 months to about 6 months, about 6 months to about 9 months, about 9 months to about 12 months, about 12 months to about 18 months, about 18 months to about 24 months, and about 24 months to about 36 months. In some embodiments, the maintenance phase dose is administered for the life of the patient.
  • the dosage of peanut protein administered to the subject during a low-dose maintenance phase is between about 10 mg and about 100 mg peanut protein.
  • the dose of the maintenance phase is between about 10 mg and about 20 mg peanut protein, about 20 mg to about 30 mg peanut protein, about 30 mg to about 40 mg peanut protein, about 40 mg to about 50 mg peanut protein, about 50 mg to about 60 mg peanut protein, about 60 mg to about 70 mg peanut protein, about 70 mg to about 80 mg peanut protein, about 80 mg to about 90 mg peanut protein, or about 90 mg to about 100 mg peanut protein.
  • the dose of the maintenance phase is about 10 mg peanut protein, about 15 mg peanut protein, about 20 mg peanut protein, about 25 mg peanut protein, about 30 mg peanut protein, about 35 mg peanut protein, about 40 mg peanut protein, about 45 mg peanut protein, about 50 mg peanut protein, about 55 mg peanut protein, about 60 mg peanut protein, about 65 mg peanut protein, about 70 mg peanut protein, about 75 mg peanut protein, about 80 mg peanut protein, about 85 mg peanut protein, about 90 mg peanut protein, about 95 mg peanut protein, or about 100 mg peanut protein.
  • the up-dosing phase of an oral immunotherapy comprises administering to the patient a series of escalating doses, beginning with a lower dose than the highest dose of the oral immunotherapy and ending with the highest dose of the oral immunotherapy.
  • Each dose in the series of doses is administered periodically, such as daily.
  • Each dose in the series can comprise daily administration of the peanut protein composition for a period of time, such as about 1 week to about 4 weeks, such as about 2 weeks. After the completion of a particular dose in the series for a period of time, treatment can be advanced to a higher dose in the series.
  • the up-dosing phase of the treatment comprises a series of between 2 and 10 different dose levels.
  • the subject can advance to the next dose level in the series of the up-dosing phase. If a subject does not tolerate a particular dose level during the up-dosing phase for a period of time, the subject may repeat the current dose level in the series. Alternatively, if a subject does not tolerate a particular dose level during the up-dosing phase for a period of time, the subject may return to an earlier dose level in the series.
  • the duration of the up-dosing phase therefore depends on the specific responses of the subject. The subject may repeat doses in the series as many times as necessary to achieve the highest dose in the series.
  • the up-dosing phase ends when the highest dose is tolerated for two weeks.
  • the pharmaceutical composition of peanut protein of a dose administered during the up-dosing phase comprises between about 0.5 mg and about 5,000 mg of peanut protein, such as about 0.5 mg to about 10 mg peanut protein, about 10 mg to about 100 mg peanut protein, about 100 mg to about 300 mg peanut protein, about 300 mg to about 500 mg peanut protein, about 500 mg to about 1,000 mg peanut protein, about 1,000 mg to about 2,000 mg peanut protein, or about 2,000 mg to about 5,000 mg peanut protein and values and ranges therebetween.
  • the doses of the up-dosing phase are daily administrations of the maximum tolerated dose of the initial escalation phase, such as 3 mg or 6 mg peanut protein, followed by a series of doses of about 12 mg peanut protein, about 20 mg peanut protein, about 40 mg peanut protein, about 80 mg peanut protein, about 120 mg peanut protein, about 160 mg peanut protein, about 200 mg peanut protein, about 240 mg peanut protein, and about 300 mg peanut protein, wherein each dosage level is administered for about 1 week to about 4 weeks (such as about 2 weeks) before advancing to the next dose in the series.
  • the doses of the up-dosing phase are daily administrations of the maximum tolerated dose of the initial escalation phase, such as 3 mg or 6 mg peanut protein, followed by a series of escalating daily doses prescribed by a subject’s medical caregiver, wherein each daily dose comprises one or more capsules or sachets selected from the group consisting of: 0.5 mg peanut protein capsules, 1 mg peanut protein capsules, 10 mg peanut protein capsules, 20 mg peanut protein capsules, 100 mg peanut protein capsules, or 300 mg peanut protein sachets, wherein each dosage level is administered for about 1 week to about 4 weeks (such as about 2 weeks) before advancing to the next dose in the series.
  • the series of doses of the up-dosing phase are distinguished by adjustment of the administered dose.
  • the size of the dose in the series of doses of the up-dosing phase are adjusted periodically, such as between once every week and once every six weeks.
  • the up-dosing phase comprises weekly dose adjustment, dose adjustment every two weeks, dose adjustment every third week, dose adjust every fourth week, dose adjustment every fifth week, dose adjustment every sixth week, or adjustment as needed based on the judgment of the subject’s medical caregiver.
  • the dose may be increased to the next scheduled dose in the series, lowered to a previous in the series in response to an allergic adverse event, maintained for an additional interval at the current dose in the series, increased to a higher dose in the series based on the judgment of the subject’s medical caregiver, or decreased to a lower dose in the series based on the judgment of the subject’s medical caregiver.
  • the up-dosing phase is adjusted at any time based on the judgment of the subject’s medical caregiver that the subject did not tolerate the current dose in the series.
  • the up-dosing phase proceeds until the subject achieves the final dose in the up dosing series.
  • the up-dosing phase is about 1 month to about 6 months, such as about 1 month to about 3 months, or about 3 months to about 6 months.
  • the up-dosing phase is about 6 months to about 2 years, such as about 6 months to about 1 year, about 1 year to about 18 months, or about 18 months to about 2 years.
  • the up-dosing phase continues for 22 weeks to 2 years, depending on the number of dose reductions and re-escalations and dose level repeats, through doses of 12 mg peanut protein, 20 mg peanut protein, 40 mg peanut protein, 80 mg peanut protein, 120 mg peanut protein, 160 mg peanut protein, 200 mg peanut protein, 240 mg peanut protein, and terminating at 300 mg peanut protein.
  • the up-dosing phase terminates when the subject tolerates the scheduled dose of the final dose in the series of the up-dosing phase for 2 weeks, thereby beginning the maintenance phase.
  • Each dose of the series of the up-dosing phase may be scheduled to last about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, or values and ranges therebetween. Based on the observation of an allergic adverse event, a subject’s caregiver may repeat the subject’s current dose in up-dosing series. A particular portion with a particular dose may be repeated as many times as necessary, such as once, two times, three times, or four times, or more, to adequately desensitize a subject to that dose, such as when the subject no longer experiences a moderate or serious allergic adverse event upon accidental (or deliberate) exposure to the food allergen.
  • the oral immunotherapy includes an initial escalation phase preceding the up-dosing phase.
  • the initial escalation phase can ensure the safety and suitability of oral immunotherapy for a particular subject.
  • the initial escalation phase is administered over a short period, such as one or two days, at an appropriate medical facility, such as a doctor’s office or allergy clinic.
  • the subject is usually closely monitored by a medical caregiver, who can provide interventions such as epinephrine, albuterol, and diphenhydramine in the event of an allergic adverse reaction that necessitates intervention.
  • the initial escalation phase of the oral immunotherapy includes administration of a plurality of small doses of the peanut protein composition to the subject.
  • the small doses can be spaced by a period of time, such as about 10 minutes to about 60 minutes, and can include 1, 2, 3, 4, or 5 or more doses.
  • the initial escalation phase may comprise doses between about 0.5 mg and about 6 mg peanut protein, such as about 0.5 mg to about 1.5 mg peanut protein, about 1.5 mg to about 3 mg peanut protein, or about 3 mg to about 6 mg peanut protein.
  • the initial escalation phase comprises an incremental escalation over one day from about 0.5 mg peanut protein to a maximum of about 6 mg peanut protein in a single day, with single doses of about 0.5 mg, about 1 mg, about 1.5 mg, about 3 mg, and about 6 mg of peanut protein, wherein tolerance of the 3 mg or 6 mg peanut protein dose indicates the subject can safely proceed to an up-dosing phase of an oral immunotherapy.
  • compositions for Oral Immunotherapy are Compositions for Oral Immunotherapy
  • compositions for treating peanut allergy are described in detail in U.S. Publication No. 2014/0271721, the contents of which are incorporated by reference herein in its entirety.
  • Exemplary methods for preparing peanut protein formulations are described in detail in U.S. Publication No. 2014/0271836, the contents of which are incorporated by reference herein in its entirety.
  • a subject having a peanut allergy can be treated for the peanut allergy by
  • the peanut protein composition is preferably a pharmaceutical composition comprising one or more peanut allergen proteins for treating peanut allergy.
  • peanut proteins may be isolated from peanut flour and, optionally, further comprise one or more diluents, one or more glidants, and one or more lubricants.
  • the pharmaceutical composition of peanut protein comprises between about 0.05% to about 100% w/w of peanut protein.
  • the pharmaceutical composition of peanut protein comprises characterized peanut protein.
  • the characterized peanut protein comprises characterized peanut allergen proteins Ara hi, Ara h2, and/or Ara h6.
  • a final formulation for treating peanut allergy comprises peanut flour, comprising characterized peanut allergen proteins Ara hi, Ara h2, and/or Ara h6, formulated with a diluent, a glidant, and a lubricant in graduated doses comprising capsules containing between about 0.5 and about 1,000 mg of peanut protein for administration in up-dosing, maintenance, and/or initial escalation phases of an oral immunotherapy.
  • the pharmaceutical composition of peanut protein for administration in a maintenance phase of an oral immunotherapy may comprise a maintenance phase dose of between about 10 mg to about 100 mg peanut protein.
  • the maintenance phase dose comprises between about 100 mg to about 3000 mg peanut protein, such as more than about 100 mg peanut protein, more than about 300 mg peanut protein, more than about 500 mg peanut protein, or more than about 1,000 mg peanut protein.
  • the pharmaceutical composition of peanut protein for administration in an up-dosing phase of an oral immunotherapy comprises between about 0.5 mg and about 5,000 mg peanut protein, such as individual doses in a series of about 3 mg, about 6 mg, about 10 mg, about 12 mg, about 20 mg, about 40 mg, about 80 mg, about 100 mg, about 120 mg, about 160 mg, about 200 mg, about 240 mg, and about 300 mg peanut protein.
  • the doses of peanut protein for injection comprises between about 0.5 mg and about 5,000 mg peanut protein, such as individual doses in a series of about 3 mg, about 6 mg, about 10 mg, about 12 mg, about 20 mg, about 40 mg, about 80 mg, about 100 mg, about 120 mg, about 160 mg, about 200 mg, about 240 mg, and about 300 mg peanut protein.
  • the doses of peanut protein for injections in a non-limiting exemplary embodiment the doses of peanut protein for
  • each daily dose comprises one or more capsules or sachets selected from the group consisting of: about 0.5 mg peanut protein capsules, about 1 mg peanut protein capsules, about 10 mg peanut protein capsules, about 20 mg peanut protein capsules, about 100 mg peanut protein capsules, or about 300 mg peanut protein sachets, wherein each dosage level is administered for about 1 week to about 4 weeks (such as about 2 weeks) before advancing to the next dose.
  • an oral immunotherapy may optionally comprise an initial escalation phase.
  • the pharmaceutical composition of peanut protein for administration in an initial escalation phase of an oral immunotherapy comprises between about 0.5 and about 6 mg of peanut protein, such as individual doses of about 0.5 mg, about 1 mg, about 1.5 mg, about 3 mg, and about 6 mg peanut protein.
  • the pharmaceutical composition of peanut protein for administration in an initial escalation phase of an oral immunotherapy comprises between about 0.5 and about 6 mg of peanut protein, such as individual doses of about 0.5 mg, about 1 mg, about 1.5 mg, about 3 mg, about 6 mg, and about 12 mg peanut protein.
  • a clinical trial is conducted with peanut- allergic children and adults. Subjects undergo an entry double-blind placebo-controlled oral food challenge (DBPCFC) and a peanut protein skin prick test (SPT). Baseline total IgE, peanut- specific IgG4, and peanut- specific IgE serum levels is assayed. Treated subjects undergo an initial escalation, followed by an up-dosing phase to a target dose of 300 mg per day of peanut protein, followed by a maintenance phase. In one treatment cohort of the clinical trial, subjects will receive a normal maintenance phase dose of 300 mg per day of peanut protein. In another treatment cohort, subjects will receive a low-dose maintenance phase dose of between 10 mg and 100 mg per day of peanut protein. The maintenance phase will proceed for a scheduled period of at least 3 months.
  • DBPCFC placebo-controlled oral food challenge
  • SPT peanut protein skin prick test
  • a subject diagnosed with peanut allergy is treated by a peanut protein oral immunotherapy.
  • the subject undergoes an up-dosing phase to 300 mg peanut protein followed by a maintenance phase.
  • a daily dose of approximately 100 mg peanut protein.
  • the subject receives lower daily doses such as 60 mg per day, 30 mg per day, and finally 10 mg per day of peanut protein.
  • the safety and efficacy of the oral immunotherapy is assessed throughout the maintenance phase by any of an oral food challenge, a SPT, incidence of allergic adverse events, and/or serum IgE and/or IgG4 levels.
  • the reactivity of the subject to accidental ingestion of peanut is recorded if it occurs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des procédés d'immunothérapie orale améliorés pour traiter une allergie à l'arachide. Dans certains modes de réalisation, l'invention concerne des procédés de traitement d'un sujet pour une allergie à l'arachide par une immunothérapie orale comprenant une phase de surdosage et une phase d'entretien, le procédé comprenant l'administration quotidienne au sujet d'une faible dose pendant la phase d'entretien.
PCT/US2020/034311 2019-05-23 2020-05-22 Procédés de traitement d'allergie à l'arachide par immunothérapie orale avec entretien à faible dose WO2020237181A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962852159P 2019-05-23 2019-05-23
US62/852,159 2019-05-23

Publications (1)

Publication Number Publication Date
WO2020237181A1 true WO2020237181A1 (fr) 2020-11-26

Family

ID=73459477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/034311 WO2020237181A1 (fr) 2019-05-23 2020-05-22 Procédés de traitement d'allergie à l'arachide par immunothérapie orale avec entretien à faible dose

Country Status (1)

Country Link
WO (1) WO2020237181A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11229673B2 (en) 2019-05-10 2022-01-25 Société des Produits Nestlé S.A. Methods for improving the quality of life of a patient with a peanut allergy
WO2024085750A1 (fr) * 2022-10-17 2024-04-25 Vini Mini B.V. Prévention des allergies aux noix et aux graines chez l'être humain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150328294A1 (en) * 2012-10-30 2015-11-19 Monash University Novel Immunotherapeutic Molecules and Uses Thereof
US20160263212A1 (en) * 2015-02-23 2016-09-15 Antera Therapeutics Inc. Compositions and methods for tolerizing the immune system to allergens
US9481716B2 (en) * 2011-03-17 2016-11-01 Cambridge Univeristy Hospitals NHS Foundation Trust Treatment for peanut allergy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9481716B2 (en) * 2011-03-17 2016-11-01 Cambridge Univeristy Hospitals NHS Foundation Trust Treatment for peanut allergy
US20150328294A1 (en) * 2012-10-30 2015-11-19 Monash University Novel Immunotherapeutic Molecules and Uses Thereof
US20160263212A1 (en) * 2015-02-23 2016-09-15 Antera Therapeutics Inc. Compositions and methods for tolerizing the immune system to allergens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GREENHAWT, MATTEW: "STOPping peanut allergy: the saga of food oral immunotherapy", THE LANCET, vol. 383, no. 9925, 12 April 2014 (2014-04-12), pages 1272 - 1274, XP055761659 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11229673B2 (en) 2019-05-10 2022-01-25 Société des Produits Nestlé S.A. Methods for improving the quality of life of a patient with a peanut allergy
WO2024085750A1 (fr) * 2022-10-17 2024-04-25 Vini Mini B.V. Prévention des allergies aux noix et aux graines chez l'être humain

Similar Documents

Publication Publication Date Title
Buchanan et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy
EP2686013B1 (fr) Traitement pour l'allergie à l'arachide
US11369676B2 (en) Methods of oral immunotherapy
Scurlock Oral and sublingual immunotherapy for treatment of IgE-mediated food allergy
Yu et al. The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial
US20220221468A1 (en) Systemic allergic response risk assessment in peanut oral immunotherapy
WO2020237181A1 (fr) Procédés de traitement d'allergie à l'arachide par immunothérapie orale avec entretien à faible dose
Gruzelle et al. Benefits of baked milk oral immunotherapy in French children with cow's milk allergy
Land et al. Oral desensitization for food hypersensitivity
Khayatzadeh et al. A safe and effective method for wheat oral immunotherapy
Ibáñez‐Sandín et al. Oral immunotherapy in severe cow’s milk allergic patients treated with omalizumab: Real life survey from a Spanish registry
Moran et al. Is clinical tolerance possible after allergen immunotherapy?
US20230090380A1 (en) Methods for improving the quality of life of a patient with a peanut allergy
Makita et al. Long-term prognosis after wheat oral immunotherapy
Geldmacher Long-term cholinesterase inhibitor therapy for Alzheimer's disease: practical considerations for the primary care physician
US20200054738A1 (en) Peanut oral immunotherapy with maintenance dose
US20200230206A1 (en) Peanut oral immunotherapy dosing schedule for missed doses
Judd et al. Successful administration of a 1-day imported fire ant rush immunotherapy protocol
Machinena et al. Oral immunotherapy protocol for hen’s egg allergic children: Improving safety
Wedi Urticaria
Petroni et al. Treatment of Single and Multiple Food Allergies with ADP101: Results of the Harmony Phase 1/2 Trial
Dantzer et al. Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial
Elliott et al. Peanut (Arachis hypogaea) Allergen Powder-dnfp (Palforzia)
Giesser et al. Updates
Moss RISK OF ANAPHYLAXIS AFTER VACCINATION OF CHILDREN AND ADOLESCENTS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20809711

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20809711

Country of ref document: EP

Kind code of ref document: A1